Read More

Praxis Precision Medicines Announces Licensing And Collaboration Agreement With Tenacia Biotechnology For Ulixacaltamide In Greater China; To Receive Proceeds Of $15M And Eligible To Receive Up To $264M In Milestone Payments As Well As Tiered Royalties

Collaboration leverages Tenacia's expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of $15 million and is

PRAX